Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any study assessment is performed~* Diagnosis of visual impairment exclusively due to ME secondary to BRVO~* BCVA score at Screening and Baseline between 73 and 19 letters (ETDRS)~Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Stroke or myocardial infarction less than 3 months before Screening~* Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline.~* Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye~* Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye~* Neovascularization of the iris or neovascular glaucoma in the study eye~* Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline~* Panretinal laser photocoagulation within 3 months before Baseline or anticipated or scheduled within the next 3 months following Baseline in the study eye~* Focal or grid laser photocoagulation within 4 months before Baseline in the study eye~* Use of intra- or periocular corticosteroids (including sub-Tenon) within 3 months before Screening in the study eye~* Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1-ranibizumab monotherapy (Type: EXPERIMENTAL): Ranibizumab 0.5 mg
- 2-ranibizumab with laser (Type: EXPERIMENTAL): Ranibizumab 0.5 mg + laser
- 3-laser monotherapy (Type: ACTIVE_COMPARATOR): Laser monotherapy with Ranibizumab 0.5 mg from Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).